SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Sana Biotechnology, Inc. for misleading statements regarding its financial health and product candidates during the specified Class Period from March 17, 2023, to November 17, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Sana was at significant risk of insufficient funds to maintain operations and advance product candidates [5]. - It alleges that the product candidates SC291, SC379, and SG299 were less promising than represented, and that funding for these candidates would likely be decreased or discontinued [5]. - Defendants are accused of overstating Sana's financial capacity, leading to materially false and misleading public statements [5]. Group 2: Participation Information - Investors who purchased Sana securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties must act before May 20, 2025, to serve as lead plaintiff [3][6]. - The Rosen Law Firm encourages investors to select qualified counsel with a successful track record in securities class actions [4].